Clincosm LogoSign in Get a demo

Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

Sponsor
Guangdong Raynovent Biotech Co., Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT05108051
Collaborator
(none)
36
Enrollment
1
Location
3
Arms
3.9
Actual Duration (Months)
9.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Phase 1, Open-Label, Three-Period, Single-center Study to Assess the Pharmacokinetic Interactions Between ZSP1273 and Oseltamivir in Healthy Subjects
Actual Study Start Date :
Nov 19, 2020
Actual Primary Completion Date :
Mar 17, 2021
Actual Study Completion Date :
Mar 17, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: sequence 1

Period 1: study of ZSP1273's pharmacokinetics at steady state； Period 2: study of Oseltamivir's pharmacokineticsat at steady state； Period 3: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state.

Drug: ZSP1273
ZSP1273 tablets 600mg administered orally once daily

Drug: Oseltamivir
Oseltamivir 75mg administered orally twice daily
Experimental: sequence 2

Period 1: study of Oseltamivir's pharmacokineticsat at steady state; Period 2: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 3: study of ZSP1273's pharmacokinetics at steady state.

Drug: ZSP1273
ZSP1273 tablets 600mg administered orally once daily

Drug: Oseltamivir
Oseltamivir 75mg administered orally twice daily
Experimental: sequence 3

Period 1: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 2: study of ZSP1273's pharmacokinetics at steady state; Period 3: study of Oseltamivir's pharmacokineticsat at steady state.

Drug: ZSP1273
ZSP1273 tablets 600mg administered orally once daily

Drug: Oseltamivir
Oseltamivir 75mg administered orally twice daily

Outcome Measures

Primary Outcome Measures

  1. Plasma pharmacokinetics [pre-dose and up to 72hours post-dose]

    Tmax

  2. Plasma pharmacokinetics [pre-dose and up to 72hours post-dose]

    t1/2

  3. Plasma pharmacokinetics [pre-dose and up to 72hours post-dose]

    Cmax

  4. Plasma pharmacokinetics [pre-dose and up to 72hours post-dose]

    AUC0-∞

  5. Plasma pharmacokinetics [pre-dose and up to 72hours post-dose]

    CL/F

  6. Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) [up to 37days]

    TEAEs will be summarized displaying the number of TEAEs along with the number and percentage of participants with at least one TEAE according to: Number of AEs, Severity and relation to study drug.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Males and female subjects between 18-45 years (Both inclusive);

  • Body weight is no less than 50kg in males and no less than 45kg in females.Body mass index (BMI) 18~26 kg/m2 (Both inclusive); BMI is determined by the following equation: BMI = weight/height2 (kg/m2);

  • Subjects (including partners) are willing to voluntarily use effective contraception from screening to 3 months after the last study drug administration.

Exclusion Criteria:

  • Known history of allergic constitution (multiple drugs especially with ZSP1273 or oseltamivir and its preparation of the main ingredient allergy, food allergy);

  • Subjects who donated blood or bleeding profusely(> 450 mL)in the 3 months preceding study screening;

  • History or presence of any disease or condition known to increase the risk of bleeding, eg.hemorrhoids, acute gastritis or gastric and duodenal ulcer, etc;

  • Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening;

  • Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of drug metabolic enzymes ，is intended to be taken in combination 28 days prior to screening or during the study period；

  • Participated in another clinical research study or received any investigational products within 3 months prior to dosing;

  • Presence of clinically significant abnormalities in ECG , QTcB>450ms in males,or QTcB>470ms in females;

  • Any of the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases) that are clinically significant in clinical laboratory examination or other clinical findings within 6 months prior to screening;

  • Breast-feeding women or those with positive pregnancy test results;

  • Subjects who should not be included in the study in the opinion of the Investigator.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong China 510000

Sponsors and Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Guangdong Raynovent Biotech Co., Ltd
ClinicalTrials.gov Identifier:
NCT05108051
Other Study ID Numbers:
  • ZSP1273-20-05
First Posted:
Nov 4, 2021
Last Update Posted:
Nov 4, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Oseltamivir

Study Results

No Results Posted as of Nov 4, 2021